Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) reported revenue ahead of Wall Streets expectations in Q3 CY2025, but sales fell by 3.7% year on year to $699.9 million. The company expects ...
As of Thursday, November 06, QuidelOrtho Corporation’s QDEL share price has dipped by 13.50%, which has investors questioning if this is right time to buy.
Get key Q3 2025 earnings insights for QuidelOrtho (QDEL): margin gains, core growth, narrowed guidance, and innovation focus.
Despite a 4% revenue drop, QuidelOrtho Corp (QDEL) focuses on organic growth and international market expansion to drive ...
QuidelOrtho Receives FDA 510(k) Clearance for VITROStm Immunodiagnostic Products hs Troponin I Assay
The U.S. Food and Drug Administration ("FDA") has granted QuidelOrtho Corporation ("QuidelOrtho"), a global leader of in vitro diagnostics, 510(k) clearance for the VITROS hs Troponin I Reagent ...
StockStory.org on MSN
Why QuidelOrtho (QDEL) Stock Is Down Today
What Happened? Shares of healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) fell 12.8% in the morning session after it reported disappointing third-quarter financial results and reduced its full ...
TipRanks on MSN
QuidelOrtho reports Q3 adjusted EPS 80c, consensus 47c
Reports Q3 revenue $700M, consensus $663.51M. “Our third quarter results reflect continued execution and meaningful progress against our strategic ...
Third quarter revenues dipped 4 percent as reported but rose 5 percent excluding results from COVID-19 testing and the donor screening business the firm is exiting.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback